HR. 946Introduced
ORPHAN Cures Act
Modifies Medicare drug price negotiation rules for orphan drugs by changing market approval timing and broadening exclusions for rare disease treatments
Plain-English overview
What this bill does
Modifies Medicare drug price negotiation rules for orphan drugs by changing market approval timing and broadening exclusions for rare disease treatments
Key points
- Modify market approval calculations
- Exclude certain orphan drugs
Current status
Where it stands
Status
Introduced
Latest action
2025-02-06 — Sponsor introductory remarks on measure. (CR H535-536)
Related context
Topics and policy areas
undefinedHealthHealth care costs and insuranceMedicarePrescription drugs